TY - JOUR T1 - MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma JF - medRxiv DO - 10.1101/19007740 SP - 19007740 AU - Christopher E. Lietz AU - Cassandra Garbutt AU - William T. Barry AU - Vikram Deshpande AU - Yen-Lin Chen AU - Santiago A. Lozano-Calderon AU - Yaoyu Wang AU - Brian Lawney AU - David Ebb AU - Gregory M. Cote AU - Zhenfeng Duan AU - Francis J. Hornicek AU - Edwin Choy AU - G. Petur Nielsen AU - Benjamin Haibe-Kains AU - John Quackenbush AU - Dimitrios Spentzos Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/10/03/19007740.abstract N2 - Background There is a lack of well validated biomarkers in osteosarcoma, a rare, recalcitrant disease with variable outcome and poorly understood biologic behavior, for which treatment standards have stalled for decades. The only standard prognostic factor in osteosarcoma remains the amount of pathologic necrosis following pre-operative chemotherapy, which does not adequately capture the biologic complexity of the tumor and has not resulted in optimized patient therapeutic stratification. New, robust biomarkers are needed to understand prognosis and better reflect the underlying biologic and molecular complexity of this disease.Methods We performed microRNA sequencing in 74 frozen osteosarcoma biopsy samples, the largest single center translationally analyzed cohort to date, and separately analyzed a multi-omic dataset from a large (n = 95) NCI supported national cooperative group cohort. Molecular patterns were tested for association with outcome and used to identify novel therapeutics for further study by integrative pharmacogenomic analysis.Results MicroRNA profiles were found predict Recurrence Free Survival (5-microRNA profile, Median RFS 59 vs 202 months, log rank p=0.06, HR 1.87, 95% CI 0.96-3.66). The profiles were independently prognostic of RFS when controlled for metastatic disease at diagnosis and pathologic necrosis following chemotherapy in multivariate Cox proportional hazards regression (5-microRNA profile, HR 3.31, 95% CI 1.31–8.36, p=0.01). Strong trends for survival discrimination were observed in the independent NCI dataset, and transcriptomic analysis revealed the downstream microRNA regulatory targets are also predictive of survival (median RFS 17 vs 105 months, log rank p=0.007). Additionally, DNA methylation patterns held prognostic significance. Through machine learning based integrative pharmacogenomic analysis, the microRNA biomarkers identify novel therapeutics for further study and stratified application in osteosarcoma.Conclusions Our results support the existence of molecularly defined phenotypes in osteosarcoma associated with distinct outcome independent of clinicopathologic features. We validated candidate microRNA profiles and their associated molecular networks for prognostic value in multiple independent datasets. These networks may define previously unrecognized osteosarcoma subtypes with distinct molecular context and clinical course potentially appropriate for future application of tailored treatment strategies in different patient subgroups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by R01CA178908 to Dimitrios Spentzos, R35CA220523 to John Quackenbush, and the Casper Colson philanthropic donation to Dimitrios Spentzos and the Sarcoma Program at the MGH Cancer Center. Data collection was supported by the Jennifer Hunter Yates Foundation, the Kenneth Stanton Sarcoma Fund, and the Cassandra Moseley Fund to the MGH Sarcoma Data Repository (PI: Dr Yen-Lin Chen). The funding bodies had no role in the design of the study and collection, analysis, interpretation of data, or in writing the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe independent NCI TARGET datasets are available through the data matrix at https://ocg.cancer.gov/programs/target/data-matrix . https://ocg.cancer.gov/programs/target/data-matrix ER -